EP0804218A4 - - Google Patents

Info

Publication number
EP0804218A4
EP0804218A4 EP95914756A EP95914756A EP0804218A4 EP 0804218 A4 EP0804218 A4 EP 0804218A4 EP 95914756 A EP95914756 A EP 95914756A EP 95914756 A EP95914756 A EP 95914756A EP 0804218 A4 EP0804218 A4 EP 0804218A4
Authority
EP
European Patent Office
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP95914756A
Other versions
EP0804218A1 (en
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of EP0804218A1 publication Critical patent/EP0804218A1/en
Publication of EP0804218A4 publication Critical patent/EP0804218A4/xx
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/14011—Deltaretrovirus, e.g. bovine leukeamia virus
    • C12N2740/14022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
EP95914756A 1994-03-17 1995-03-17 Product and process for regulating signal transduction pathways Withdrawn EP0804218A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US215116 1988-07-05
US21511694A 1994-03-17 1994-03-17
PCT/US1995/003438 WO1995024915A1 (en) 1994-03-17 1995-03-17 Product and process for regulating signal transduction pathways

Publications (2)

Publication Number Publication Date
EP0804218A1 EP0804218A1 (en) 1997-11-05
EP0804218A4 true EP0804218A4 (cs) 1997-11-12

Family

ID=22801724

Family Applications (1)

Application Number Title Priority Date Filing Date
EP95914756A Withdrawn EP0804218A1 (en) 1994-03-17 1995-03-17 Product and process for regulating signal transduction pathways

Country Status (4)

Country Link
EP (1) EP0804218A1 (cs)
JP (1) JPH09512704A (cs)
CA (1) CA2184631A1 (cs)
WO (1) WO1995024915A1 (cs)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5976819A (en) * 1995-11-21 1999-11-02 National Jewish Medical And Research Center Product and process to regulate actin polymerization in T lymphocytes
JP2001503260A (ja) * 1996-10-23 2001-03-13 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア 改良されたワクチン
US6420338B1 (en) * 1997-06-13 2002-07-16 New York University Medical Center Inhibition of the Src kinase family pathway as a method of treating HBV infection and hepatocellular carcinoma
EP1156826B1 (en) 1999-02-25 2009-05-27 National Jewish Center For Immunology And Respiratory Medicine Product and method for treatment of conditions associated with receptor-desensitization
WO2003006060A1 (fr) * 2001-07-09 2003-01-23 Kyowa Hakko Kogyo Co., Ltd. Inhibiteurs de la liaison au domaine sh3

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992013001A1 (en) * 1991-01-18 1992-08-06 New York University A RECEPTOR TYROSINE KINASE TARGET PROTEIN cDNA CLONING METHOD AND hGRB PROTEINS
CA2054602A1 (en) * 1991-10-31 1993-05-01 Anthony Pawson Method for assaying for a substance that affects an sh2-phosphorylated ligand regulatory system
WO1993021317A1 (en) * 1992-04-16 1993-10-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services ISOLATION, CHARACTERIZATION, AND USE OF THE HUMAN β SUBUNIT OF THE HIGH AFFINITY RECEPTOR FOR IMMUNOGLOBULIN E
EP0568925A2 (en) * 1992-05-03 1993-11-10 Yeda Research And Development Co. Ltd. TNF receptor action modulation
WO1994017095A1 (en) * 1993-01-29 1994-08-04 Ariad Pharmaceuticals, Inc. Analogs of receptor tyrosine activation motifs and therapeutic uses thereof
WO1994018832A1 (en) * 1993-02-26 1994-09-01 Dana-Farber Cancer Institute, Inc. Cd4 mediated modulation of lipid kinases
WO1995001376A1 (en) * 1993-06-30 1995-01-12 Pharmacia S.P.A. Peptide inhibitors of mitogenesis and motogenesis
WO1996003649A1 (en) * 1994-07-22 1996-02-08 The University Of North Carolina At Chapel Hill Src SH3 BINDING PEPTIDES AND METHODS OF ISOLATING AND USING SAME
WO1996026961A2 (en) * 1995-02-28 1996-09-06 National Jewish Center For Immunology And Respiratory Medicine Peptidyl compounds comprising an itim motif which regulate hematopoietic function and their use
US7815749B2 (en) * 2006-06-29 2010-10-19 Hitachi Metals, Ltd. Method for manufacturing semi-hard magnetic material and semi-hard magnetic material

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992013001A1 (en) * 1991-01-18 1992-08-06 New York University A RECEPTOR TYROSINE KINASE TARGET PROTEIN cDNA CLONING METHOD AND hGRB PROTEINS
CA2054602A1 (en) * 1991-10-31 1993-05-01 Anthony Pawson Method for assaying for a substance that affects an sh2-phosphorylated ligand regulatory system
WO1993021317A1 (en) * 1992-04-16 1993-10-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services ISOLATION, CHARACTERIZATION, AND USE OF THE HUMAN β SUBUNIT OF THE HIGH AFFINITY RECEPTOR FOR IMMUNOGLOBULIN E
EP0568925A2 (en) * 1992-05-03 1993-11-10 Yeda Research And Development Co. Ltd. TNF receptor action modulation
WO1994017095A1 (en) * 1993-01-29 1994-08-04 Ariad Pharmaceuticals, Inc. Analogs of receptor tyrosine activation motifs and therapeutic uses thereof
WO1994018832A1 (en) * 1993-02-26 1994-09-01 Dana-Farber Cancer Institute, Inc. Cd4 mediated modulation of lipid kinases
WO1995001376A1 (en) * 1993-06-30 1995-01-12 Pharmacia S.P.A. Peptide inhibitors of mitogenesis and motogenesis
WO1996003649A1 (en) * 1994-07-22 1996-02-08 The University Of North Carolina At Chapel Hill Src SH3 BINDING PEPTIDES AND METHODS OF ISOLATING AND USING SAME
WO1996026961A2 (en) * 1995-02-28 1996-09-06 National Jewish Center For Immunology And Respiratory Medicine Peptidyl compounds comprising an itim motif which regulate hematopoietic function and their use
US7815749B2 (en) * 2006-06-29 2010-10-19 Hitachi Metals, Ltd. Method for manufacturing semi-hard magnetic material and semi-hard magnetic material

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 9310, Derwent World Patents Index; Class B04, AN 93-085859, XP002030008 *
J.C. CAMBIER: "New nomenclature for the Reth motif (or ARH1/TAM/ARAM/YXXL)", IMMUNOLOGY TODAY, vol. 16, no. 2, February 1995 (1995-02-01), CAMBRIDGE GB, pages 110, XP000673072 *
J.C. CAMBIER: "Signal transduction by T- and B-cell antigen receptors: converging structures and concepts", CURRENT OPINIONS IN IMMUNOLOGY, vol. 4, no. 3, June 1992 (1992-06-01), PHILADELPHIA US, pages 257 - 264, XP000197369 *
See also references of WO9524915A1 *

Also Published As

Publication number Publication date
CA2184631A1 (en) 1995-09-21
JPH09512704A (ja) 1997-12-22
AU699662B2 (en) 1998-12-10
WO1995024915A1 (en) 1995-09-21
AU2187495A (en) 1995-10-03
EP0804218A1 (en) 1997-11-05

Similar Documents

Publication Publication Date Title
TW270191B (cs)
DK0677466T3 (cs)
EP0669187A3 (cs)
EP0665261A3 (cs)
FR2728074B1 (cs)
TW277002B (cs)
EP0667387A3 (cs)
DE69535748D1 (cs)
TW268922B (cs)
EP0667627A3 (cs)
GB9415472D0 (cs)
NO941578D0 (cs)
DK0685247T3 (cs)
TW288953B (cs)
ECSMU940030U (cs)
ECSDI940194S (cs)
IN180127B (cs)
CU22450A3 (cs)
CU22453A3 (cs)
ITTO950941A0 (cs)
ITRM950842A0 (cs)
DK40195A (cs)
IN180934B (cs)
ECSDI940191S (cs)
IN178960B (cs)

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19960926

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 19970924

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20001004

RIC1 Information provided on ipc code assigned before grant

Ipc: 7C 07K 14/705 B

Ipc: 7C 07K 7/08 A